← All Intorio, CORP filings

Intorio, CORP 10-Q quarterly reports

Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.

OTC.Pink
ITOR
Intorio, CORP
10-Q: Intorio Corp. Reports Q3 2025 Results: Revenue Remains Low Amidst Going Concern Concerns
Intorio Corp.'s Q3 2025 results reveal minimal revenue and a net loss, raising concerns about the company's ability to continue as a going concern.
OTC.Pink
ITOR
Intorio, CORP
10-Q: Intorio, Corp. Reports Q2 Results: Name Change and New Leadership Focus on Functional Medicine
Intorio, Corp. files its Form 10-Q for the quarter ended August 31, 2024, revealing a net loss and a shift in business direction under new leadership, focusing on functional medicine.
OTC.Pink
ITOR
Intorio, CORP
10-Q: Intorio Corp. Reports Q1 2025 Results: Focus Shifts to Functional Medicine Under New Leadership
Intorio Corp. reports a net loss for Q1 2025 and outlines a new business direction focusing on functional medicine under new leadership following a major ownership change.